FOAMIX PHARMACEUTICALS LTD.
FOMX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for FOMX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2019.
Tracking 5 pipeline candidates for FOAMIX PHARMACEUTICALS LTD..
Run FOAMIX PHARMACEUTICALS LTD. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available FOAMIX PHARMACEUTICALS LTD. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 3.62
Lead: Approved
5 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is FOAMIX PHARMACEUTICALS LTD.'s lead drug candidate?
FOAMIX PHARMACEUTICALS LTD.'s most advanced tracked candidate is amzeeq (Approved) for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris.
What therapeutic areas does FOAMIX PHARMACEUTICALS LTD. focus on?
FOAMIX PHARMACEUTICALS LTD. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.